Puma Biotechnology Inc
PBYI
Company Profile
Business description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Contact
10880 Wilshire Boulevard
Suite 2150
Los AngelesCA90024
USAT: +1 424 248-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
185
Stocks News & Analysis
video
ASX dividend stocks for 2025
With dividend yields at 25-year lows, it's time to rethink ASX stocks for income according to James Gruber.
stocks
Did the market overreact to Westpac results?
Shares fell more than 6.50 percent after the bank reported results.
stocks
Investors overly negative on undervalued ASX share
Road to profitability is in sight as management continues to take the right steps.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,756.70 | 55.20 | -0.63% |
| CAC 40 | 8,206.56 | 17.43 | 0.21% |
| DAX 40 | 22,844.50 | 46.41 | 0.20% |
| Dow JONES (US) | 44,503.28 | 42.80 | -0.10% |
| FTSE 100 | 8,766.73 | 1.28 | -0.01% |
| HKSE | 22,976.81 | 360.58 | 1.59% |
| NASDAQ | 20,012.71 | 14.06 | -0.07% |
| Nikkei 225 | 39,270.40 | 96.15 | 0.25% |
| NZX 50 Index | 13,051.12 | 17.81 | -0.14% |
| S&P 500 | 6,120.45 | 5.82 | 0.10% |
| S&P/ASX 200 | 8,481.00 | 56.10 | -0.66% |
| SSE Composite Index | 3,324.49 | 31.34 | -0.93% |